Real‐life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study-Reference-Cited by-同舟云学术

Real‐life effectiveness of Risankizumab according to body mass index: Results of an Italian multicentre retrospective study

Published:2023-04-24 Issue:8 Volume:37 Page:
ISSN:0926-9959
Container-title:Journal of the European Academy of Dermatology and Venereology
language:en
Short-container-title:Acad Dermatol Venereol

Author:

Dragotto Martina¹,Capalbo Eugenio¹,Cartocci Alessandra²^ORCID,Manzo Margiotta Flavia³^ORCID,Michelucci Alessandra³,Rosi Elia⁴^ORCID,Ricceri Federica⁵,Simoni Barbara⁶,Savarese Imma⁷,Milanesi Nicola⁷,Rossari Susanna⁸,Magnano Michela⁸^ORCID,Romanelli Marco³,Rubegni Pietro¹,Prignano Francesca⁴^ORCID,Di Cesare Antonella⁴^ORCID,Panduri Salvatore³,Pescitelli Leonardo⁹,Trovato Emanuele¹^ORCID

Affiliation:

1. Dermatology Section, Department of Medical, Surgical and Neurological Science University of Siena Siena Italy

2. Department of Medical Biotechnology University of Siena Siena Italy

3. Department of Dermatology University of Pisa Pisa Italy

4. Unit of Dermatology, Department of Surgery and Translational Medicine University of Florence Florence Italy

5. Unit of Dermatology San Donato Hospital Arezzo Italy

6. Unit of Dermatology Hospital of Campo di Marte Lucca Italy

7. Department of Dermatology San Jacopo Hospital Pistoia Italy

8. Unit of Dermatology Versilia Hospital Lido di Camaiore, Lucca Italy

9. Unit of Dermatology San Giuseppe Hospital, Empoli Florence Italy

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.19117

Reference10 articles.

1. The Immunogenetics of Psoriasis

2. Tuscany consensus for the treatment of moderate–severe psoriasis: update and focus on practical guidelines for place in therapy of anti‐IL‐17 and anti‐IL‐23 biologics;Prignano F;Ital J Dermatol Venerol,2022

3. Place in therapy of anti-IL-17 and 23 in psoriasis according to the severity of comorbidities: a focus on cardiovascular disease and metabolic syndrome

4. Management of psoriasis as a systemic disease: what is the evidence?

5. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Potential of Targeting the JAK/STAT Pathway in Psoriasis: Focus on TYK2 Inhibition;Journal of Clinical Medicine;2024-05-24